RGN6024 is the August 2025 Molecular Cancer Therapeutics cover story
Reglagene’s preclinical development candidate, RGN6024, is the cover story and “First Disclosure” highlight in the August issue of Molecular Cancer Therapeutics, a top-tier journal from the American Association for Cancer Research.
RGN6024 is a brain-penetrant therapy designed to treat glioblastoma and other brain cancers. This recognition highlights the strength of Reglagene’s science and the urgent need for better options in neuro-oncology.
Reglagene is also honored that “Drug Hunter” named RGN6024 a Molecule of the Month, placing us alongside innovations from Novartis, BMS, and others.
Long supported by Desert Angels, the Reglagene Team is pushing hard toward first-in-human studies. Reglagene is actively in discussion with prospective partners who are committed to solving brain cancer, and welcomes conversations with future partners and collaborators.
? Read the MCT article: click here to read the full article
? Explore Drug Hunter’s roundup: click here for summary citation (summary only, full article requires registration)